Stock Events

Stock Events

Corgi IP Licensing & Royalties 

$24.52
148
+$0.11+0.45% 14:24 Today

Statistics

Day High
24.4
Day Low
24.35
52W High
28.06
52W Low
23.83
Volume
12
Avg. Volume
330
Mkt Cap
43.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Expense Ratio

0.35%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Earnings

16NovExpected
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Q1 2026
Next
-2.86
-0.49
1.89
4.26
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-17.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTNT. It's not an investment recommendation.
Apple
21
AAPL
Palantir Technologies
19
PLTR
Tesla
17
TSLA
Amazon
16
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap208.49B
Amgen develops therapeutics in areas similar to Palatin, including reproductive health and cardiovascular diseases, making them direct competitors in the biopharmaceutical market.
Pfizer
PFE
Mkt Cap157.65B
Pfizer competes with Palatin in the development of novel drugs, including treatments in sexual health, where Palatin has a significant focus.
Lilly(Eli) &
LLY
Mkt Cap1.03T
Eli Lilly offers products in men's health and other areas that overlap with Palatin's focus, particularly in treatments for conditions like erectile dysfunction.
Abbvie
ABBV
Mkt Cap466.45B
AbbVie, with its broad range of pharmaceutical products, competes in the same therapeutic areas as Palatin, including women's health and hormonal therapies.
Merck
MRK
Mkt Cap362.35B
Merck operates in various healthcare segments that compete with Palatin, including the development of drugs for sexual health and cardiovascular diseases.
Novartis
NVS
Mkt Cap266.8B
Novartis competes with Palatin in multiple areas, including cardiovascular and metabolic conditions, through its extensive research and development in these fields.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol Myers Squibb's diverse range of pharmaceutical products in areas like cardiovascular diseases places it in competition with Palatin Technologies.
GSK
GSK
Mkt Cap100.62B
GlaxoSmithKline has a presence in the sexual health market, making it a competitor to Palatin, especially in the development of treatments for related conditions.
Astrazeneca
AZN
Mkt Cap257.57B
AstraZeneca's work in cardiovascular and metabolic diseases competes with Palatin's research and development efforts in similar therapeutic areas.

Holdings

About

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Show more...
CEO
Carl Spana
Employees
29
Country
United States
ISIN
US2189466483
WKN
000A3DTUW

Listings

STU
DE
PTN.STU
BATS
US
PTNT
LSE
GB
0KF3.LSE
XNAS
US
PTN

0 Comments

Share your thoughts

FAQ

What is Corgi IP Licensing & Royalties stock price today?▼
The current price of PTNT is $24.52 USD — it has increased by +0.45% in the past 24 hours. Watch Corgi IP Licensing & Royalties stock price performance more closely on the chart.
What is Corgi IP Licensing & Royalties stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on BATS exchange Corgi IP Licensing & Royalties stocks are traded under the ticker PTNT.
Is Corgi IP Licensing & Royalties stock price growing?▼
PTNT stock has risen by +2.72% compared to the previous week, the month change is a -1.76% fall, over the last year Corgi IP Licensing & Royalties has showed a +139.27% increase.
What is Corgi IP Licensing & Royalties market cap?▼
Today Corgi IP Licensing & Royalties has the market capitalization of 43.63M
When is the next Corgi IP Licensing & Royalties earnings date?▼
Corgi IP Licensing & Royalties is going to release the next earnings report on November 16, 2026.
What were Corgi IP Licensing & Royalties earnings last quarter?▼
PTNT earnings for the last quarter are -0.37 USD per share, whereas the estimation was -1.24 USD resulting in a +70.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corgi IP Licensing & Royalties revenue for the last year?▼
Corgi IP Licensing & Royalties revenue for the last year amounts to 0 USD.
What is Corgi IP Licensing & Royalties net income for the last year?▼
PTNT net income for the last year is -17.31M USD.
How many employees does Corgi IP Licensing & Royalties have?▼
As of September 25, 2026, the company has 29 employees.
In which sector is Corgi IP Licensing & Royalties located?▼
Corgi IP Licensing & Royalties operates in the Health & Wellness sector.
When did Corgi IP Licensing & Royalties complete a stock split?▼
The last stock split for Corgi IP Licensing & Royalties was on August 12, 2025 with a ratio of 1:50.
Where is Corgi IP Licensing & Royalties headquartered?▼
Corgi IP Licensing & Royalties is headquartered in CRANBURY, United States.